

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Issuer in the United States.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

**NOTICE OF RESTRUCTURING EFFECTIVE DATE
IN THE GRAND COURT OF THE CAYMAN ISLANDS
FINANCIAL SERVICES DIVISION
CAUSE NO. FSD 0391 OF 2023 (JAJ)
IN THE MATTER OF SECTION 86 OF THE COMPANIES ACT
(2023 REVISION)
AND
IN THE MATTER OF YESTAR HEALTHCARE
HOLDINGS COMPANY LIMITED (巨星醫療控股有限公司)**

This announcement is made by Yestar Healthcare Holdings Company Limited (巨星醫療控股有限公司) (the “**Company**”) pursuant to Rules 13.09(2) and 37.47(B) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 24 January 2024, 20 February 2024 and 1 March 2024 in relation to the Scheme (collectively, the “**Announcements**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as in the Announcements. This Notice is circulated in accordance with clause 7.5 of the Scheme.

The Company is hereby pleased to announce that the Restructuring Effective Date occurred on 14 March 2024.

For a Blocked Scheme Creditor who is eligible to receive Consent Fees, the final deadline for it to submit the documentation required to validly claim its portion of the Consent Fee is the Bar Time, being 7:00 a.m. (Cayman Islands time)/8:00 p.m. (Hong Kong time) on the date falling three (3) Business Days before the Holding Period Expiry Date. Blocked Scheme Creditors should refer to the Transaction Website (<https://projects.morrowsodali.com/yestar>) for further details.

By order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
CEO and Executive Director

14 March 2024

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.